---
title: Nabumetone + Paracetamol
description: >-
  Nabumetone + Paracetamol is a combination medication primarily prescribed for
  the relief of pain and inflammation associated with musculoskeletal conditions
  such as osteoarthritis and rheumatoid arthritis.  It combines the analgesic
  and anti-inflammatory properties of both drugs for enhanced pain...
is_banned: false
lastModified: '2025-09-22T17:22:09.603Z'
faqs:
  - q: >-
      What is the recommended dosage for Nabumetone + Paracetamol?**


      **A:** The recommended dosage varies depending on the individual and the
      severity of the condition. Consult a physician for guidance. Typical adult
      dosages involve combining standard dosages of individual components.
    a: >-
      A:** The recommended dosage varies depending on the individual and the
      severity of the condition. Consult a physician for guidance. Typical adult
      dosages involve combining standard dosages of individual components.
  - q: >-
      What are the common side effects of this combination?**


      **A:** Common side effects may include gastrointestinal discomfort,
      headache, and dizziness.
    a: >-
      A:** Common side effects may include gastrointestinal discomfort,
      headache, and dizziness.
  - q: Is this combination safe for pregnant women?
    a: ''
---
## **Usage**

Nabumetone + Paracetamol is a combination medication primarily prescribed for the relief of pain and inflammation associated with musculoskeletal conditions such as osteoarthritis and rheumatoid arthritis.  It combines the analgesic and anti-inflammatory properties of both drugs for enhanced pain relief.

**Pharmacological Classification:**

* Nabumetone: Nonsteroidal anti-inflammatory drug (NSAID)
* Paracetamol: Analgesic and antipyretic

**Mechanism of Action:**

Nabumetone is a prodrug converted in the liver to its active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA).  6-MNA inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins, which are key mediators of pain and inflammation. Paracetamol's mechanism is not fully understood, but it is believed to inhibit COX enzymes primarily in the central nervous system, thereby reducing pain and fever. The combination provides synergistic pain relief by targeting different pathways.

## **Alternate Names**

This fixed-dose combination does not have an international nonproprietary name (INN). It is referred to by the names of its constituents, Nabumetone and Paracetamol.

**Brand Names:**

Several brand names exist for this combination product in different regions, though specific brand names in India would require verification with local pharmaceutical resources.  Examples include the individual components marketed under brand names like Relafen (Nabumetone) and Crocin (Paracetamol) though a combined formulation may be available under various regional or local names which require verification with medical databases from within India.

## **How It Works**

**Pharmacodynamics:**  Nabumetone, through its active metabolite 6-MNA, exerts anti-inflammatory, analgesic, and antipyretic effects primarily by inhibiting COX-1 and COX-2 enzymes, leading to a decrease in prostaglandin synthesis. Paracetamol's analgesic and antipyretic effects are thought to be mediated through central COX inhibition, with minimal peripheral anti-inflammatory action.

**Pharmacokinetics:**

* **Nabumetone:**  Administered orally, it's rapidly absorbed and metabolized in the liver to 6-MNA.  6-MNA is highly protein-bound and has a relatively long half-life (approximately 24 hours), allowing for once-daily dosing.  Excretion is primarily renal.
* **Paracetamol:** Orally administered paracetamol is also rapidly absorbed. It undergoes hepatic metabolism through glucuronidation and sulfation pathways, with a small fraction metabolized by cytochrome P450 to a potentially hepatotoxic metabolite. It has a shorter half-life (approximately 2-3 hours) compared to Nabumetone. Excretion is primarily renal.


**Mode of Action:** Both drugs reduce pain and inflammation. The combination provides synergistic pain relief as they work through distinct but related pathways.

**Receptor Binding/Enzyme Inhibition:** Both Nabumetone (through its metabolite) and Paracetamol primarily target COX enzymes but with different selectivity and tissue distributions.

**Elimination Pathways:**  Both drugs are predominantly eliminated via the kidneys.


## **Dosage**

The dosage of Nabumetone + Paracetamol varies depending on the severity of the condition and patient-specific factors.  Always consult with a qualified physician for personalized dosage recommendations.  

### **Standard Dosage**

#### **Adults:**

A common starting dose might be Nabumetone 500 mg plus Paracetamol 500 mg twice daily, or a higher dose based on medical advice. The Nabumetone component is often administered as a single daily dose due to its longer half-life.  Maximum daily doses should be considered and would need to be verified based on the latest available combined dosage information within India.

#### **Children:**

This combination is generally not recommended for children unless specifically prescribed by a physician who will determine the appropriate dosage. Pediatric dosing of paracetamol alone is weight-based. Nabumetone dosage in children needs expert assessment.



#### **Special Cases:**

* **Elderly Patients:**  Lower starting doses and careful monitoring are recommended due to age-related decline in renal and hepatic function.
* **Patients with Renal Impairment:** Dose reduction of Nabumetone is necessary depending on the degree of impairment. Paracetamol dosage may also need adjustment.
* **Patients with Hepatic Dysfunction:**  Nabumetone dosage should be reduced, and Paracetamol use requires careful consideration due to the risk of hepatotoxicity.
* **Patients with Comorbid Conditions:** Individualized dosage adjustments may be required for patients with conditions such as diabetes, cardiovascular disease, or other relevant comorbidities.

### **Clinical Use Cases**

The use of Nabumetone + Paracetamol in these specific clinical settings is not standardized.  Pain management in these contexts requires careful consideration of patient-specific factors and the potential risks and benefits of using NSAIDs. Paracetamol alone may be preferred.

* **Intubation:** Not typically indicated.
* **Surgical Procedures:** Post-operative pain may be better managed with other analgesics based on patient tolerance.
* **Mechanical Ventilation:** Not typically indicated.
* **Intensive Care Unit (ICU) Use:** Not typically indicated.
* **Emergency Situations:** Not typically indicated.


### **Dosage Adjustments**

Dosage adjustments are crucial for patients with renal or hepatic dysfunction, as well as for elderly patients and those with certain comorbidities. Regular monitoring of renal and liver function is necessary, particularly during long-term therapy.


## **Side Effects**

### **Common Side Effects**

Gastrointestinal issues (dyspepsia, nausea, abdominal pain, constipation, diarrhea), headache, dizziness, rash, and itching.

### **Rare but Serious Side Effects**

Gastrointestinal bleeding or ulceration, myocardial infarction, stroke, hepatotoxicity (particularly with Paracetamol overdose), Stevens-Johnson syndrome, and allergic reactions.

### **Long-Term Effects**

Chronic kidney disease, cardiovascular complications, and gastrointestinal issues may occur with prolonged use, especially at higher doses.


### **Adverse Drug Reactions (ADR)**

Severe allergic reactions (anaphylaxis, angioedema), severe skin reactions (toxic epidermal necrolysis), and acute liver failure (Paracetamol overdose).



## **Contraindications**

Hypersensitivity to either drug, history of severe allergic reaction to NSAIDs or paracetamol, severe hepatic impairment, active peptic ulcer disease, severe heart failure, recent coronary artery bypass graft (CABG) surgery, and during the third trimester of pregnancy.


## **Drug Interactions**

* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding.
* **Antihypertensives:** May reduce their effectiveness.
* **Lithium:**  May increase lithium levels.
* **Methotrexate:**  May increase methotrexate toxicity.
* **Alcohol:**  May increase the risk of gastrointestinal bleeding and hepatotoxicity.



## **Pregnancy and Breastfeeding**

Nabumetone is contraindicated during the third trimester of pregnancy.  Use during the first and second trimesters should be limited to cases where the potential benefit outweighs the risk.  Limited data are available on Paracetamol concentrations in breast milk; use with caution while breastfeeding.

## **Drug Profile Summary**

* **Mechanism of Action:**  COX inhibition (Nabumetone/6-MNA), central COX inhibition (Paracetamol).
* **Side Effects:** See above.
* **Contraindications:** See above.
* **Drug Interactions:** See above.
* **Pregnancy & Breastfeeding:**  See above.
* **Dosage:**  See above.
* **Monitoring Parameters:**  Renal and liver function tests, blood pressure, signs of gastrointestinal bleeding.



## **Popular Combinations**

In some cases, Nabumetone or Paracetamol might be combined with other medications for specific clinical indications but information on combined Nabumetone and Paracetamol is limited. Further investigation in Indian databases may be required to ascertain other locally accepted combinations.


## **Precautions**

* Monitor for signs of gastrointestinal bleeding, renal or hepatic dysfunction.
* Assess cardiovascular risk factors.
* Avoid alcohol or limit intake.
* Use with caution in patients with asthma.


## **FAQs (Frequently Asked Questions)**



### **Q1: What is the recommended dosage for Nabumetone + Paracetamol?**

**A:** The recommended dosage varies depending on the individual and the severity of the condition. Consult a physician for guidance. Typical adult dosages involve combining standard dosages of individual components. 

### **Q2: What are the common side effects of this combination?**

**A:** Common side effects may include gastrointestinal discomfort, headache, and dizziness.

### **Q3: Is this combination safe for pregnant women?**

